In a small phase Ib study in this issue of Cell, Ribas et al. report that the combination of intralesional injection of a modified human herpes simplex virus and systemic anti-PD-1 treatment resulted in a 62% response rate in patients with metastatic melanoma, accompanied by enhanced T cell infiltration in virus-injected lesions.
Talimogene laherparepvec is a human herpes simplex virus (HSV) that selectively infects and replicates in human cancer cells (Liu et al., 2003) . Through engineered expression of granulocytemacrophage colony-stimulating factor (GM-CSF), talimogene laherparepvec attracts and matures antigen-presenting cells to and within the tumor microenvironment, thereby inducing anti-tumor T cell responses (Kaufman et al., 2010) . Intralesional injection of talimogene laherparepvec into melanoma metastases has been shown to be safe, leading to durable regressions of both injected and sometimes non-injected lesions in patients with stage IIIB/C and IV melanoma. In a randomized phase III trial comparing talimogene laherparepvec to subcutaneous GM-CSF administration, the drug showed an overall response rate of 26.4%, resulting in FDA and EMA approval (Andtbacka et al., 2015) . In this issue of Cell, Ribas et al. tested the effect of combining talimogene laherparepvec and the anti-PD-1 drug pembrolizumab on patients with metastatic melanoma in a phase Ib clinical trial (Ribas et al., 2017) . In the 21 patients that were enrolled in this study, the overall response rate was an impressive 62% (with 33% complete responses), clearly exceeding the overall response rate observed for either treatment alone. Importantly, no unexpected or doselimiting toxicities were observed.
The profound clinical activity of this combinatory treatment is a testament to our increased understanding of the requirements for T cell-mediated control of human cancer. Specifically, response to PD-1 blockade can be predicted with a reasonable degree of precision by four internally consistent markers. First, clinical response to anti-PD-1 in melanoma is correlated with the pre-therapy presence of CD8 tumor-infiltrating lymphocytes (TIL) at the invasive tumor margin (Tumeh et al., 2014) . Second, responses are more frequently observed in tumors with a high mutational burden, in line with the notion that T cell recognition of neo-antigens plays a major role in anti-PD-1 activity (Hugo et al., 2016) . Third, overall response rate to anti-PD-1 is correlated with PD-L1 expression by the melanoma cells (Daud et al., 2016) . As PD-L1 expression is generally driven by IFN-g secreted by activated melanoma-specific T cells, tumor PD-L1 expression can be considered a reflection of an ongoing anti-tumor immune response. Fourth, RNA sequence analysis of tumor biopsies has revealed that the presence of an IFN-g gene signature is likewise correlated with response to anti-PD-1 (Ayers et al., 2017) . Together, these data provide strong evidence for a model in which anti-PD-1 serves to unleash the activity of a previously generated tumor-specific T cell pool. Put differently, in patients in whom such a tumor-reactive T cell infiltrate is absent, the substrates for anti-PD-1 to work on are lacking. The current study now shows that intralesional injection of oncolytic virus can induce T cell infiltration in tumors with low or no pre-treatment TIL, indicating that the viral therapy is capable of changing the local microenvironment from an immunologically cold, or T cell excluded, to an inflamed tumor. In their study, the investigators made use of a run-in with injection of talimogene laherparepvec only, before initiating the combination with pembrolizumab. Paired biopsies from before and after viral injection allowed them to thereby study the effects induced by virus administration, revealing recruitment of both CD4 and CD8 T cells, and other, PD-L1-expressing immune cells, following viral injection.
It is worth noting that despite efforts to obtain biopsies and blood samples from many of these patients, the immunological mechanism that culminated in the observed clinical responses remains to some extent speculative (Figure 1) . The local secretion of GM-CSF may have been expected to attract dendritic cells (DCs) and other innate immune cells and to lead to increased production of mediators of natural antiviral immune responses, such as type I interferons. However, analysis of the repeat biopsies did not provide evidence for either of these mechanisms. Conceivably, tumor cell destruction and antigen uptake and presentation by DCs takes place shortly after viral injection, in a time frame much shorter than the 6 weeks between the matched biopsies that could be analyzed. Importantly though, two other pieces of data provided by the authors are highly informative. First, although increased accumulation of T cells was primarily observed in the injected lesions, some evidence was also obtained for an increase in immune infiltrate at non-injected sites in some patients, a finding consistent with the induction of systemic anti-melanoma immune responses. The fact that the vaccine has impact on noninjected and even, be it rarely, visceral metastases likewise points in the direction of at least some systemic immunity. Second, contrary to what has been observed in anti-PD-1-treated patients with stage IV melanoma, response to combination therapy did not show a detectable association with pre-treatment intratumoral CD8 T cell levels or IFN-g gene signature. In other words, by inducing an intratumoral T cell response, viral therapy may be removing the value of the pre-treatment immune CD8 infiltrate as a predictive marker in this combination therapy.
Although the response data coming from this small phase Ib study are highly promising, we need to await the results of the ongoing randomized phase III trial to properly understand the potential synergy between local administration of a viral vaccine and PD-1 blockade. In addition, such a larger study will also be of value to address another key question that is raised by the current work. Specifically, which subpopulation of patients may benefit most from combination therapy over single-agent PD-1 blockade? Is this the group of patients with highly mutagenized tumors that failed to attract T cells, or is combination therapy lowering the average mutational burden that is required for clinical response? If the latter, implications for the many other tumor types with lower mutational burdens could also be profound.
The field of cancer immunotherapy is evolving rapidly and serves as a prime example of the long-term value of fundamental scientific research. The publication of this study by Ribas et al. in Cell emphasizes how much clinical and basic research in this field have become intertwined. 
